Increase in short-term risk of rejection in heart transplant patients receiving granulocyte colony-stimulating factor.

[1]  J. Sochman,et al.  Bone marrow suppression and associated consequences in patients after heart transplantation: A 6-year retrospective review. , 2015, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[2]  S. Melby,et al.  Have risk factors for mortality after heart transplantation changed over time? Insights from 19 years of Cardiac Transplant Research Database study. , 2014, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[3]  S. Grajek,et al.  Induction therapy, tacrolimus plasma concentration, and duration if intensive care unit stay are risk factors for peripheral leucopenia following heart transplantation. , 2014, Annals of transplantation.

[4]  J. Barbot,et al.  Tacrolimus‐induced neutropenia in a cardiac transplant patient , 2014, Pediatric transplantation.

[5]  S. Hunt,et al.  Granulocyte colony-stimulating factor therapy is associated with a reduced incidence of acute rejection episodes or allograft vasculopathy in heart transplant recipients. , 2013, Transplantation proceedings.

[6]  D. Kuypers,et al.  Tacrolimus-induced neutropenia in renal transplant recipients. , 2011, Clinical journal of the American Society of Nephrology : CJASN.

[7]  V. Emery,et al.  Cytomegalovirus in transplantation – challenging the status quo , 2007, Clinical transplantation.

[8]  H. Valantine,et al.  Peripheral Blood Leukocyte Counts in Cytomegalovirus Infected Heart Transplant Patients: Impact of Acute Disease Versus Subclinical Infection , 2006, Transplantation.

[9]  L. Mestroni,et al.  Drug therapy in the heart transplant recipient: part II: immunosuppressive drugs. , 2004, Circulation.

[10]  L. Mestroni,et al.  Drug therapy in the heart transplant recipient: part I: cardiac rejection and immunosuppressive drugs. , 2004, Circulation.

[11]  R. Rubin,et al.  Clinical Approach to Infection in the Compromised Host , 2002, Springer US.

[12]  R. Rubin,et al.  Safety and efficacy of granulocyte colony‐stimulating factor in kidney and liver transplant recipients , 2000 .

[13]  T. Habermann,et al.  Granulocyte colony-stimulating factor in severe chemotherapy-induced afebrile neutropenia. , 1997, The New England journal of medicine.

[14]  A. Chong,et al.  Granulocyte colony-stimulating factor immunomodulation in the rat cardiac transplantation model. , 1996, Transplantation.

[15]  S. Hariharan,et al.  Role of granulocyte colony stimulating factor (G-CSF) in reversing neutropenia in renal allograft recipients. , 1996, Clinical transplantation.

[16]  Squiers Ec,et al.  Use of granulocyte-macrophage colony-stimulating factor for reversal of neutropenia following combined kidney-pancreas transplantation. , 1995 .

[17]  A. Mazuecos,et al.  Worsening of renal function in a renal transplant patient treated with granulocyte colony-stimulating factor. , 1995, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[18]  S. Leurgans,et al.  THE USE OF GRANULOCYTE COLONY‐STIMULATING FACTOR AFTER LIVER TRANSPLANTATION , 1995, Transplantation.

[19]  S. Spector,et al.  A randomized trial of three antipneumocystis agents in patients with advanced human immunodeficiency virus infection. NIAID AIDS Clinical Trials Group. , 1995, The New England journal of medicine.

[20]  A. Murday,et al.  GRANULOCYTE COLONY‐STIMULATING FACTOR: A NEW APPLICATION FOR CYTOMEGALOVIRUS‐INDUCED NEUTROPENIA IN CARDIAC ALLOGRAFT RECIPIENTS , 1994, Transplantation.

[21]  D. Sutherland.  State of the art in pancreas transplantation. , 1994, Transplantation proceedings.

[22]  E. Thervet,et al.  Use of granulocyte-macrophage colony-stimulating factor in leukopenic renal transplant recipients. , 1994, Transplantation proceedings.

[23]  Lieschke Gj,et al.  Granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor (2). , 1992, The New England journal of medicine.

[24]  A. Burgess,et al.  Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor , 1992 .

[25]  M. Crowther,et al.  Granulocyte macrophage colony-stimulating factor for the therapy of cytomegalovirus and ganciclovir-induced leukopenia in a renal transplant recipient. , 1992, Transplantation.

[26]  K. Kawabe,et al.  Colony-stimulating factor for treatment of leukopenia after kidney allografting. , 1991, Transplantation proceedings.

[27]  F. Herrmann,et al.  Hematologic effects of recombinant human granulocyte colony-stimulating factor in patients with malignancy. , 1989, Blood.

[28]  D. Metcalf,et al.  The molecular control of cell division, differentiation commitment and maturation in haemopoietic cells , 1989, Nature.

[29]  B. Roser,et al.  Reversal of transplantation immunity by liver grafting , 1981, Nature.

[30]  G. Klintmalm,et al.  Successful liver transplantation from crossmatch-positive donors. , 1981, Transplantation proceedings.

[31]  H. Bismuth,et al.  Specific transplantation tolerance induced by spontaneously tolerated liver allograft in inbred strains of rats. , 1980, Transplantation.

[32]  E. Squiers,et al.  Use of granulocyte-macrophage colony-stimulating factor for reversal of neutropenia following combined kidney-pancreas transplantation. , 1995, Transplantation proceedings.

[33]  R. Busuttil,et al.  Reversal of neutropenia with granulocyte colony-stimulating factor without precipitating liver allograft rejection. , 1993, Transplantation.

[34]  E. Mohler,et al.  The use of granulocyte colony-stimulating factor in the treatment of fever and neutropenia in a heart transplant patient. , 1993, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.